Johnson and Johnson combines Biosense with Cordis subsidiary:
This article was originally published in Clinica
Johnson & Johnson is to merge its Cordis Webster company with Biosense, an acquisition from last October. According to J&J, the move means the company, now to be known as Biosense Webster, will "better serve the needs of cardiologists" and apply its medical sensor technology. Cordis Webster was acquired in 1996 as part of the Cordis deal. The new company's worldwide president will be James Dennis, formerly president of St Jude's cardiac rhythm management division.
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.